Presentations

• Stenehjem D., F. Albright, A. Gou, L. Chen, K. Raimundo, H. Bauer, D. Brixner. “Real-world response monitoring and tolerability of imatinib treated chronic myeloid leukemia patients captured in a retrospective research registry.” Poster session presented at ASCO Meeting, Chicago, IL. Poster, Accepted, 06/2012.
• Stenehjem D.D, F. Albright, K. Kuo, K. Raimundo, D. Brixner. “Evaluating Contemporary Practice in CML via a Retrospective Research Registry of Patients across a Comprehensive Cancer Center Database.” International Society For Pharmacoeconomics and Outcomes Research, 17th Annual International Meeting. Washington, DC. Poster, Accepted, 03/27/2012.
• Stenehjem D., K. Kuo, H. Bauer, R. Barney, F. Albright, D. Brixner. “Outcomes and treatment patterns of hepatocellular carcinoma patients stratified by staging-guided treatment categories in a patient-centered retrospective research registry.” ISPOR 5th Asia-Pacific Conference. Taipei, Taiwan. Poster, Submitted, 03/2012.
• Creation of a Chronic Myeloid Leukemia Retrospective Outcomes Research Registry. Department of Pharmacotherapy Faculty Seminar. Presentation, Presented, 02/2012.
• Oral Chemotherapy: Something to ‘nib_ble on. USHP Annual Meeting. Invited Talk/Keynote, Presented, 09/2011.
• Oral Chemotherapy: Something to ‘nib_ble on. Presentation, Presented, 03/2011.
• Stenehjem, D.D., D.I. Brixner, F. Albright, J.E. Biskupiak, J.A. Gilreath, D. Sageser; S.A. Sanders. “Factors affecting clinical response to tyrosine kinase inhibitors in chronic myeloid leukemia.” University HealthSystem Consortium Pharmacy Council Meeting. Anaheim, CA. Poster, Presented, 12/2010.
• Stenehjem, D.D., J.S. Blake, B.H. Sederholm, J.E. Biskupiak. “Effects of p-glycoprotein inhibitors and modulators on acute epileptic events.” University HealthSystem Consortium Pharmacy Council Meeting. Las Vegas, NV. Poster, Presented, 12/2009.

Publications

• Patel SB, Stenehjem DD, Gill DM, Tantravahi SK, Agarwal AM, Hsu J, Vuong W, Pal SK & Agarwal N (2016). Everolimus Versus Temsirolimus in Metastatic Renal Cell Carcinoma After Progression With Previous Systemic Therapies. Clinical genitourinary cancer. Vol. 14, 153-9. Published, 03/01/2016.
• Stenehjem DD, Bellows BK, Yager KM, Jones J, Kaldate R, Siebert U & Brixner DI (2016). Cost-Utility of a Prognostic Test Guiding Adjuvant Chemotherapy Decisions in Early-Stage Non-Small Cell Lung Cancer. The oncologist. Vol. 21, 196-204. Published, 02/01/2016.
• Bailey H, Stenehjem DD, Sharma S. Panobinostat for the treatment of multiple myeloma: the evidence to date. Journal of Blood Medicine. October 2015:269-276. doi:10.2147/JBM.S69140. Published, 10/2015.
• Kuo KL, Stenehjem DD, Albright F, Brixner DI. Treatment Patterns and Outcomes in Patients with Hepatocellular Carcinoma Stratified by Stage-Guided Treatment Categories. Journal of the National Comprehensive Cancer Network. 2015;13(8):987-994. Published, 08/2015.
• Siebert U, Jahn B, Rochau U, et al. on behalf of the Oncotyrol HTA & Outcomes Research Working Group. Oncotyrol – Center for Personalized Cancer Medicine: Methods and Applications of Health Technology Assessment and Outcomes Research. Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen. July 2015. doi:10.1016/j.zefq.2015.06.012. Published, 06/2015.
• Tantravahi SK, Albertson D, Agarwal AM, Straubhar AM, Poole A, Ravulapati S, Hawatmeh JS, Liu T, Stenehjem DD (co-senior author), N Agarwal. Survival outcomes and tumor IMP3 expression in patients with sarcomatoid metastatic renal cell carcinoma. Journal of Oncology. 2015;2015(2):1–6. Published, 02/2015.
• Rochau U, Sroczynski G, Wolf D, Schmidt S, Jahn B, Kluibenschaedl M, Conrads-Frank A, Stenehjem DD, Brixner D, Radich J, Gastl G, Siebert U. Cost-Effectiveness of the Sequential Application of Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia. Leukemia and Lymphoma. 2015:1–11. doi:10.3109/10428194.2014.982635. Published, 01/2015.
• Bailey, Erin B., Wells, Chesley E., Tantravahi, Srinivas K., Agarwal, Neeraj, Batten, Julia A., Patel, Shiven B., Agarwal, Archana M., Stenehjem, David D., Straubhar, Alli M. & Poole, Austin (2014). Correlation of Degree of Hypothyroidism With Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors. Elsevier BV. Published, 2014.
• Gilreath, Jeffrey A., Rodgers, George M. & Stenehjem, David (2014). Diagnosis and treatment of cancer-related anemia. Wiley-Blackwell. , n/a-n/a. Published, 2014.
• Reese R, Patel S, Stenehjem DD, Garrido-Laguna I. Response to nab-paclitaxel plus gemcitabine in a patient with primary resistance to FOLFIRINOX. Journal of Gastrointestinal Cancers. 2014. doi:10.1007/s12029-014-9662-3. Published, 11/2014.
• Bailey EB, Tantravahi SK, Poole A, Agarwal AM, Straubhar AM, Batten JA, Wells CE, Stenehjem DD (co-senior author), N Agarwal. Correlation of degree of hypothyroidism with survival outcomes in patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor receptor tyrosine kinase inhibitors. Clinical Genitourinary Cancer. 2014. doi:10.1016/j.clgc.2014.11.002. Published, 11/2014.
• Stenehjem DD, Yoo M, Unni S, Singhal M, Bauer H, Saverno K, Quah C, Masaquel A, Brixner DI. Assessment of single-institution HER2 testing patterns, rate of HER2+ disease and utilization of trastuzumab in early breast cancer. Breast Cancer: Targets and Therapy. 2014:6 169–177. Published, 08/2014.
• Stenehjem DD, Albright FS, Kuo K-L, Raimundo K, Bauer H, Shami PJ, Deininger MW, Chen L, Brixner DI. Response Monitoring, Tolerability and Effectiveness of Imatinib Treatment for Chronic Myeloid Leukemia in a Retrospective Research Database. J Natl Compr Canc Netw. 2014;12(8):1113–1121. Published, 07/2014.
• Gilreath JA, Stenehjem DD, Rodgers GM. Diagnosis and treatment of cancer-related anemia. Am J Hematol. 2014; 89(2):203-212. Published, 06/2014.
• Akerley, Wallace, Nelson, Richard E. & Stenehjem, David (2013). A comparison of individualized treatment guided by VeriStrat with standard of care treatment strategies in patients receiving second-line treatment for advanced non-small cell lung cancer: A cost-utility analysis. Elsevier BV. Vol. 82(3), 461-468. Published, 2013.
• Bellows, B.K., Brixner, D., Jiao, T., Jones, J., Kaldate, R.R., Rhien, T. & Stenehjem, D. (2013). Literature Review and Assessment to Populate a Decision-Analytic Model Evaluating a Novel Prognostic in Early Lung Cancer. Elsevier BV. Vol. 16(7), A589-A590. Published, 2013.
• Anderson, L., Brixner, D., Cheng, Y., Colonna, S., Neumayer, L., Stenehjem, D., Udomaksorn, S. & Welch, B. (2013). Evaluation of Variable Relevance and Accessibility to Support Personalized Medicine in Breast Cancer. Elsevier BV. Vol. 16(7), A393. Published, 2013.
• Brixner, D., Jahn, B., Kluibenschaedl, M., Kuo, K.L., Rochau, U., Siebert, U. & Stenehjem, D. (2013). The United States Physican Survey to Populate a Decision-Analytic Model for the Treatment of Chronic Myeloid Leukemia. Elsevier BV. Vol. 16(7), A423. Published, 2013.
• Kuo, Kuan-Ling, Saokaew, Surasak & Stenehjem, David D. (2013). The Pharmacoeconomics of Breakthrough Cancer Pain. Informa Healthcare. Vol. 27(2), 167-175. Published, 2013.
• Brixner, D., Conrads-Frank, A., Gastl, G., Jahn, B., Radich, J., Rochau, U., Schmidt, S., Siebert, U., Sroczynski, G., Stenehjem, D. & Wolf, D. (2013). Uncertainty and Cost-Effectiveness Analysis of the Sequential Application of Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia. Elsevier BV. Vol. 16(7), A409. Published, 2013.
• Kuo K-L, Saokaew S, Stenehjem DD. The Pharmacoeconomics of Breakthrough Cancer Pain. J Pain Palliat Care Pharmacother. 2013; 27(2):167-175. Published, 06/2013.
• Nelson RE, Stenehjem DD, Akerley W. A comparison of individualized treatment guided by VeriStrat with standard of care treatment strategies in patients receiving second-line treatment for advanced non-small cell lung cancer: A cost-utility analysis. Lung Cancer. 2013; 89(3):461-468. Published, 06/2013.
• Siebert, U., Jahn, B., Cai, B., Saverno, K.R., Rochau, U., Brixner, D. & Stenehjem, D. (2012). PCN153 Application of Real World Data to Inform a Breast Cancer Decision - Analytic Model in Austria and the U.S - Preliminary Outcomes of Data Collection. Elsevier BV. Vol. 15(7), A437. Published, 2012.
• Albright, F., Raimundo, K., Kuo, K.L., Brixner, D. & Stenehjem, D. (2012). PCN147 Evaluating Contemporary Practice in Cml via a Retrospective Research Registry of Patients Across a Comprehensive Cancer Center Database. Elsevier BV. Vol. 15(4), A234-A235. Published, 2012.
• Barney, R., Bauer, H., Albright, F., Kuo, K.L., Brixner, D. & Stenehjem, D. (2012). PCN13 Outcomes and Treatment Patterns of Hepatocellular Carcinoma Patients Stratified by Staging-Guided Treatment Categories in a Patient-Centered Retrospective Research Registry. Elsevier BV. Vol. 15(7), A655. Published, 2012.
• Brixner, D., Albright, F., Bauer, H., Cai, B., Stenehjem, D., Kuo, K.L. & Saokaew, S. (2012). PCN32 Treatment Patterns and Outcomes of Melanoma Patients in a Patient-Centered Retrospective Research Registry. Elsevier BV. Vol. 15(7), A414. Published, 2012.
• Kuo, K.L., Cai, B., Saokaew, S., Albright, F., Bauer, H., Brixner, D. & Stenehjem, D. (2012). PCN31 Treatments Pattern and Outcomes of Ovarian Cancer Patients in a Patient-Centered Retrospective Research Registry. Elsevier BV. Vol. 15(7), A414. Published, 2012.
• Saokaew, S., Brixner, D., Stenehjem, D., Albright, F., Bauer, H., Cai, B. & Kuo, K.L. (2012). PCN30 Treatment Patterns and Outcomes of Breast Cancer Patients in a Patient-Centered Retrospective Research Registry. Elsevier BV. Vol. 15(7), A414. Published, 2012.
• Saverno KR, Rochau PU, Stenehjem DD, Morley K, Siebert U, Brixner DI. Application of Decision-Analytic Models in Personalized Medicine for CML Treatment Decisions Made by Payers, Providers, and Patients. JMCP. 2012;18(6):1–7. Published, 06/2012.
• Gilreath, J.A., D.D. Stenehjem, and G.M. Rodgers (2012). “Total Dose Iron Dextran Infusion in Cancer Patients: Is it SaFe2+?” Journal of the National Comprehensive Cancer Network. Published, 03/2012.
• McMillian, W. D., Stenehjem, D., Saba, M. & Cirulli, J. (2011). Adaptive trial design: Its growing role in clinical research and implications for pharmacists. American Society of Health System Pharmacists. Vol. 68(9), 807-813. Published, 2011.
• Albright, F., Bollu, V., Raimundo, K., Brixner, D., Stenehjem, D., Barney, R. & Kuo, K.L. (2011). DS1 INTEGRATING DATA SOURCES TO CONDUCT COMPREHENSIVE ONCOLOGY BASED OUTCOMES RESEARCH. Elsevier BV. Vol. 14(3), A6. Published, 2011.
• Cirulli J, McMillian WD, Saba M, Stenehjem DD. Adaptive trial design: Its growing role in clinical research and implications for pharmacists. Am J Health Syst Pharm. 2011;68(9):807–813. Published, 05/2011.
  http://www.ncbi.nlm.nih.gov/pubmed/21515864
• Stenehjem DD, Hartz AMS, Bauer B, Anderson GW. Novel and emerging strategies in drug delivery for overcoming the blood-brain barrier. Future Med Chem. 2009;1(9):1623–1641. Published, 12/2009.
  http://www.ncbi.nlm.nih.gov/pubmed/21425983
• Westholm DE, Stenehjem DD, Rumbley JN, Drewes LR, Anderson GW. Competitive inhibition of organic anion transporting polypeptide 1c1-mediated thyroxine transport by the fenamate class of nonsteroidal antiinflammatory drugs. Endocrinology. 2009;150(2):1025–1032. Published, 02/2009.
  http://www.ncbi.nlm.nih.gov/pubmed/18845642